Phaseline

Targets › CHIT1

CHIT1 (Chitotriosidase-1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout Aug 2027.

Degrades chitin, chitotriose and chitobiose. May participate in the defense against nematodes and other pathogens. (UniProt, Q13231)

Open in Phaseline: the race on CHIT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
MolecureOATD-01
Chitinase-1 (CHIT1) inhibitor
CHIT1Phase 2Pulmonary SarcoidosisAug 2027

Conditions

Pulmonary Sarcoidosis (1)

Modalities

small molecule (1)

Companies

Molecure (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.